US5962490A
(en)
|
1987-09-25 |
1999-10-05 |
Texas Biotechnology Corporation |
Thienyl-, furyl- and pyrrolyl-sulfonamides and derivatives thereof that modulate the activity of endothelin
|
US6342610B2
(en)
|
1993-05-20 |
2002-01-29 |
Texas Biotechnology Corp. |
N-aryl thienyl-, furyl-, and pyrrolyl-sulfonamides and derivatives thereof that modulate the activity of endothelin
|
US6541498B2
(en)
|
1993-05-20 |
2003-04-01 |
Texas Biotechnology |
Benzenesulfonamides and the use thereof to modulate the activity of endothelin
|
US6613804B2
(en)
|
1993-05-20 |
2003-09-02 |
Encysive Pharmaceuticals, Inc. |
Biphenylsulfonamides and derivatives thereof that modulate the activity of endothelin
|
US6376523B1
(en)
|
1994-05-20 |
2002-04-23 |
Texas Biotechnology Corporation |
Benzenesulfonamides and the use thereof to modulate the activity of endothelin
|
US5846990A
(en)
*
|
1995-07-24 |
1998-12-08 |
Bristol-Myers Squibb Co. |
Substituted biphenyl isoxazole sulfonamides
|
US5977117A
(en)
|
1996-01-05 |
1999-11-02 |
Texas Biotechnology Corporation |
Substituted phenyl compounds and derivatives thereof that modulate the activity of endothelin
|
US5804585A
(en)
|
1996-04-15 |
1998-09-08 |
Texas Biotechnology Corporation |
Thieno-pyridine sulfonamides derivatives thereof and related compounds that modulate the activity of endothelin
|
HU227183B1
(en)
|
1997-04-28 |
2010-09-28 |
Encysive Pharmaceuticals Inc |
Sulfonamide derivatives and pharmaceutical compositions containing them for the treatment of endothelin-mediated disorders
|
US5783705A
(en)
|
1997-04-28 |
1998-07-21 |
Texas Biotechnology Corporation |
Process of preparing alkali metal salys of hydrophobic sulfonamides
|
JP5187991B2
(ja)
|
1997-10-17 |
2013-04-24 |
アーク・セラピューティックス・リミテッド |
レニン−アンジオテンシン系の阻害剤の使用
|
AU1591699A
(en)
*
|
1998-03-17 |
1999-10-11 |
Warner-Lambert Company |
Statin-matrix metalloproteinase inhibitor combinations
|
AU767456B2
(en)
|
1998-07-06 |
2003-11-13 |
Bristol-Myers Squibb Company |
Biphenyl sulfonamides as dual angiotensin endothelin receptor antagonists
|
US6638937B2
(en)
|
1998-07-06 |
2003-10-28 |
Bristol-Myers Squibb Co. |
Biphenyl sulfonamides as dual angiotensin endothelin receptor antagonists
|
MY125533A
(en)
*
|
1999-12-06 |
2006-08-30 |
Bristol Myers Squibb Co |
Heterocyclic dihydropyrimidine compounds
|
AU2092601A
(en)
*
|
1999-12-15 |
2001-06-25 |
Bristol-Myers Squibb Company |
Biphenyl sulfonamides as dual angiotensin endothelin receptor antagonists
|
CA2395684C
(fr)
|
1999-12-31 |
2012-01-03 |
Texas Biotechnology Corporation |
Sulfonamides et leurs derives modulant l'activite de l'endotheline
|
US7622503B2
(en)
|
2000-08-24 |
2009-11-24 |
University Of Tennessee Research Foundation |
Selective androgen receptor modulators and methods of use thereof
|
US7855229B2
(en)
*
|
2000-08-24 |
2010-12-21 |
University Of Tennessee Research Foundation |
Treating wasting disorders with selective androgen receptor modulators
|
US7919647B2
(en)
|
2000-08-24 |
2011-04-05 |
University Of Tennessee Research Foundation |
Selective androgen receptor modulators and methods of use thereof
|
US7645898B2
(en)
*
|
2000-08-24 |
2010-01-12 |
University Of Tennessee Research Foundation |
Selective androgen receptor modulators and method of use thereof
|
US6639082B2
(en)
*
|
2000-10-17 |
2003-10-28 |
Bristol-Myers Squibb Company |
Methods for the preparation of biphenyl isoxazole sulfonamides
|
AU2002241736A1
(en)
*
|
2000-12-21 |
2002-07-01 |
Bristol-Myers Squibb Company |
Method for preventing or treating pain by administering an endothelin antagonist
|
WO2002083130A1
(fr)
*
|
2001-04-16 |
2002-10-24 |
Bristol-Myers Squibb Company |
Enantiomeres de n-[[2'-[[(4,5-dimethyl-3-isoxazolyl) amino]sulfonyl]-4-(2-oxazolyl)[1,1'-biphenyl]-2-yl]methyl]-n,3,3-trimethylbutanamide
|
CA2726702A1
(fr)
|
2001-09-21 |
2003-04-03 |
Bristol-Myers Squibb Company |
Composes contenant du lactame et leurs derives en tant qu'inhibiteurs du facteur xa
|
KR20040054729A
(ko)
*
|
2001-10-18 |
2004-06-25 |
브리스톨-마이어스 스큅 컴퍼니 |
인간 글루카곤-유사-펩티드-1 모방체, 및 당뇨병 및 이와관련된 증상의 치료에 있어서 이의 용도
|
US7238671B2
(en)
*
|
2001-10-18 |
2007-07-03 |
Bristol-Myers Squibb Company |
Human glucagon-like-peptide-1 mimics and their use in the treatment of diabetes and related conditions
|
US8853266B2
(en)
|
2001-12-06 |
2014-10-07 |
University Of Tennessee Research Foundation |
Selective androgen receptor modulators for treating diabetes
|
US20070161608A1
(en)
*
|
2001-12-06 |
2007-07-12 |
Dalton James T |
Selective androgen receptor modulators for treating muscle wasting
|
US6831102B2
(en)
*
|
2001-12-07 |
2004-12-14 |
Bristol-Myers Squibb Company |
Phenyl naphthol ligands for thyroid hormone receptor
|
TW200307539A
(en)
*
|
2002-02-01 |
2003-12-16 |
Bristol Myers Squibb Co |
Cycloalkyl inhibitors of potassium channel function
|
US7772433B2
(en)
*
|
2002-02-28 |
2010-08-10 |
University Of Tennessee Research Foundation |
SARMS and method of use thereof
|
TW200403058A
(en)
*
|
2002-04-19 |
2004-03-01 |
Bristol Myers Squibb Co |
Heterocyclo inhibitors of potassium channel function
|
US7435824B2
(en)
*
|
2002-04-19 |
2008-10-14 |
Bristol-Myers Squibb Company |
Prodrugs of potassium channel inhibitors
|
US7405234B2
(en)
*
|
2002-05-17 |
2008-07-29 |
Bristol-Myers Squibb Company |
Bicyclic modulators of androgen receptor function
|
US7057046B2
(en)
*
|
2002-05-20 |
2006-06-06 |
Bristol-Myers Squibb Company |
Lactam glycogen phosphorylase inhibitors and method of use
|
AU2003276648A1
(en)
*
|
2002-06-17 |
2003-12-31 |
Bristol-Myers Squibb Company |
Benzodiazepine inhibitors of mitochondial f¿1?f¿0? atp hydrolase and methods of inhibiting f¿1?f¿0? atp hydrolase
|
MY139563A
(en)
*
|
2002-09-04 |
2009-10-30 |
Bristol Myers Squibb Co |
Heterocyclic aromatic compounds useful as growth hormone secretagogues
|
AU2003270357A1
(en)
*
|
2002-09-06 |
2004-03-29 |
Microbia, Inc. |
Inhibitors of fungal invasion
|
ES2344057T3
(es)
*
|
2002-10-23 |
2010-08-17 |
Bristol-Myers Squibb Company |
Inhibidores de la dipeptidil peptidasa iv basados en nitrilos de glicina.
|
US7098235B2
(en)
|
2002-11-14 |
2006-08-29 |
Bristol-Myers Squibb Co. |
Triglyceride and triglyceride-like prodrugs of glycogen phosphorylase inhibiting compounds
|
EP1567487A4
(fr)
*
|
2002-11-15 |
2005-11-16 |
Bristol Myers Squibb Co |
Modulateurs lies a prolyl uree a chaine ouverte de la fonction du recepteur d'androgene
|
US8309603B2
(en)
|
2004-06-07 |
2012-11-13 |
University Of Tennessee Research Foundation |
SARMs and method of use thereof
|
TW200504021A
(en)
*
|
2003-01-24 |
2005-02-01 |
Bristol Myers Squibb Co |
Substituted anilide ligands for the thyroid receptor
|
JP2006516620A
(ja)
*
|
2003-01-24 |
2006-07-06 |
ブリストル−マイヤーズ スクイブ カンパニー |
甲状腺受容体におけるシクロアルキル含有アニリドリガンド
|
CL2004000545A1
(es)
*
|
2003-03-18 |
2005-01-28 |
Pharmacia Corp Sa Organizada B |
Uso de un antagonista de los receptores de aldosterona y un antagonista de receptores de endotelina para el tratamiento o profilaxis de una condicion patologica relacionada con hipertension, disfuncion renal, insulinopatia y enfermedades cardiovascul
|
US6846836B2
(en)
*
|
2003-04-18 |
2005-01-25 |
Bristol-Myers Squibb Company |
N-substituted phenylurea inhibitors of mitochondrial F1F0 ATP hydrolase
|
US7557143B2
(en)
|
2003-04-18 |
2009-07-07 |
Bristol-Myers Squibb Company |
Thyroid receptor ligands
|
US6995183B2
(en)
*
|
2003-08-01 |
2006-02-07 |
Bristol Myers Squibb Company |
Adamantylglycine-based inhibitors of dipeptidyl peptidase IV and methods
|
US7256208B2
(en)
*
|
2003-11-13 |
2007-08-14 |
Bristol-Myers Squibb Company |
Monocyclic N-Aryl hydantoin modulators of androgen receptor function
|
US7820702B2
(en)
*
|
2004-02-04 |
2010-10-26 |
Bristol-Myers Squibb Company |
Sulfonylpyrrolidine modulators of androgen receptor function and method
|
US20050182105A1
(en)
*
|
2004-02-04 |
2005-08-18 |
Nirschl Alexandra A. |
Method of using 3-cyano-4-arylpyridine derivatives as modulators of androgen receptor function
|
US7378426B2
(en)
|
2004-03-01 |
2008-05-27 |
Bristol-Myers Squibb Company |
Fused heterotricyclic compounds as inhibitors of 17β-hydroxysteroid dehydrogenase 3
|
US7388027B2
(en)
*
|
2004-03-04 |
2008-06-17 |
Bristol-Myers Squibb Company |
Bicyclic compounds as modulators of androgen receptor function and method
|
US7696241B2
(en)
*
|
2004-03-04 |
2010-04-13 |
Bristol-Myers Squibb Company |
Bicyclic compounds as modulators of androgen receptor function and method
|
US7625923B2
(en)
|
2004-03-04 |
2009-12-01 |
Bristol-Myers Squibb Company |
Bicyclic modulators of androgen receptor function
|
US7772232B2
(en)
*
|
2004-04-15 |
2010-08-10 |
Bristol-Myers Squibb Company |
Quinazolinyl compounds as inhibitors of potassium channel function
|
US7550499B2
(en)
*
|
2004-05-12 |
2009-06-23 |
Bristol-Myers Squibb Company |
Urea antagonists of P2Y1 receptor useful in the treatment of thrombotic conditions
|
ATE493973T1
(de)
*
|
2004-06-04 |
2011-01-15 |
Teva Pharma |
Irbesartan enthaltende pharmazeutische zusammensetzung
|
US20110237664A1
(en)
*
|
2004-06-07 |
2011-09-29 |
Dalton James T |
Selective androgen receptor modulators for treating diabetes
|
US9884038B2
(en)
|
2004-06-07 |
2018-02-06 |
University Of Tennessee Research Foundation |
Selective androgen receptor modulator and methods of use thereof
|
US9889110B2
(en)
|
2004-06-07 |
2018-02-13 |
University Of Tennessee Research Foundation |
Selective androgen receptor modulator for treating hormone-related conditions
|
US7145040B2
(en)
*
|
2004-07-02 |
2006-12-05 |
Bristol-Myers Squibb Co. |
Process for the preparation of amino acids useful in the preparation of peptide receptor modulators
|
TW200611704A
(en)
*
|
2004-07-02 |
2006-04-16 |
Bristol Myers Squibb Co |
Human glucagon-like-peptide-1 modulators and their use in the treatment of diabetes and related conditions
|
US7534763B2
(en)
|
2004-07-02 |
2009-05-19 |
Bristol-Myers Squibb Company |
Sustained release GLP-1 receptor modulators
|
US7572805B2
(en)
|
2004-07-14 |
2009-08-11 |
Bristol-Myers Squibb Company |
Pyrrolo(oxo)isoquinolines as 5HT ligands
|
US7754755B2
(en)
*
|
2004-09-23 |
2010-07-13 |
Bristol-Myers Squibb Company |
Inhibitors of 15-lipoxygenase
|
US7429611B2
(en)
|
2004-09-23 |
2008-09-30 |
Bristol-Myers Squibb Company |
Indole inhibitors of 15-lipoxygenase
|
AR051446A1
(es)
*
|
2004-09-23 |
2007-01-17 |
Bristol Myers Squibb Co |
Glucosidos de c-arilo como inhibidores selectivos de transportadores de glucosa (sglt2)
|
US7517991B2
(en)
*
|
2004-10-12 |
2009-04-14 |
Bristol-Myers Squibb Company |
N-sulfonylpiperidine cannabinoid receptor 1 antagonists
|
US8143425B2
(en)
*
|
2004-10-12 |
2012-03-27 |
Bristol-Myers Squibb Company |
Heterocyclic aromatic compounds useful as growth hormone secretagogues
|
US20060128726A1
(en)
*
|
2004-11-24 |
2006-06-15 |
Xuebao Wang |
Process for preparing novel crystalline forms of (2S)-1-[[(7R)-7-(3,4-dichlorophenyl)-4,7-dihydro-5-methylpyrazolo[1,5]pyrimidine-6-yl]carbonyl]-2-(4-fluorophenyl)pyrrolidine, novel stable forms produced therein and formulations
|
US7589088B2
(en)
*
|
2004-12-29 |
2009-09-15 |
Bristol-Myers Squibb Company |
Pyrimidine-based inhibitors of dipeptidyl peptidase IV and methods
|
US7220859B2
(en)
|
2005-01-12 |
2007-05-22 |
Bristol-Myers Squibb Company |
Bicyclic heterocycles as cannabinoid receptor modulators
|
US7314882B2
(en)
*
|
2005-01-12 |
2008-01-01 |
Bristol-Myers Squibb Company |
Bicyclic heterocycles as cannabinoid receptor modulators
|
WO2006076597A1
(fr)
*
|
2005-01-12 |
2006-07-20 |
Bristol-Myers Squibb Company |
Heterocycles bicycliques constituant des modulateurs des recepteurs cannabinoides
|
US7459564B2
(en)
|
2005-01-13 |
2008-12-02 |
Bristol-Myers Squibb Company |
Substituted biaryl compounds as factor XIa inhibitors
|
US20060160850A1
(en)
*
|
2005-01-18 |
2006-07-20 |
Chongqing Sun |
Bicyclic heterocycles as cannabinoid receptor modulators
|
US7645778B2
(en)
*
|
2005-01-19 |
2010-01-12 |
Bristol-Myers Squibb Company |
Heteroaryl compounds as P2Y1 receptor inhibitors
|
US7238702B2
(en)
*
|
2005-02-10 |
2007-07-03 |
Bristol-Myers Squibb Company |
Dihydroquinazolinones as 5HT modulators
|
US20060235028A1
(en)
|
2005-04-14 |
2006-10-19 |
Li James J |
Inhibitors of 11-beta hydroxysteroid dehydrogenase type I
|
US7521557B2
(en)
|
2005-05-20 |
2009-04-21 |
Bristol-Myers Squibb Company |
Pyrrolopyridine-based inhibitors of dipeptidyl peptidase IV and methods
|
CN101282991A
(zh)
*
|
2005-05-26 |
2008-10-08 |
布里斯托尔-迈尔斯斯奎布公司 |
N-端修饰的胰高血糖素样肽-1受体调节剂
|
US7452892B2
(en)
*
|
2005-06-17 |
2008-11-18 |
Bristol-Myers Squibb Company |
Triazolopyrimidine cannabinoid receptor 1 antagonists
|
US7572808B2
(en)
*
|
2005-06-17 |
2009-08-11 |
Bristol-Myers Squibb Company |
Triazolopyridine cannabinoid receptor 1 antagonists
|
US7632837B2
(en)
*
|
2005-06-17 |
2009-12-15 |
Bristol-Myers Squibb Company |
Bicyclic heterocycles as cannabinoid-1 receptor modulators
|
US7317012B2
(en)
*
|
2005-06-17 |
2008-01-08 |
Bristol-Myers Squibb Company |
Bicyclic heterocycles as cannabinoind-1 receptor modulators
|
US20060287342A1
(en)
*
|
2005-06-17 |
2006-12-21 |
Mikkilineni Amarendra B |
Triazolopyrimidine heterocycles as cannabinoid receptor modulators
|
US7629342B2
(en)
*
|
2005-06-17 |
2009-12-08 |
Bristol-Myers Squibb Company |
Azabicyclic heterocycles as cannabinoid receptor modulators
|
ATE485269T1
(de)
*
|
2005-06-27 |
2010-11-15 |
Bristol Myers Squibb Co |
C-verknüpfte zyklische antagonisten des p2y1- rezeptors mit eignung bei der behandlung thrombotischer leiden
|
EP1896417B1
(fr)
|
2005-06-27 |
2011-03-23 |
Bristol-Myers Squibb Company |
Mimetiques lineaires de l'uree antagonistes du recepteur p2y1, utilises dans le traitement des troubles thrombotiques
|
US7714002B2
(en)
*
|
2005-06-27 |
2010-05-11 |
Bristol-Myers Squibb Company |
Carbocycle and heterocycle antagonists of P2Y1 receptor useful in the treatment of thrombotic conditions
|
US7728008B2
(en)
*
|
2005-06-27 |
2010-06-01 |
Bristol-Myers Squibb Company |
N-linked heterocyclic antagonists of P2Y1 receptor useful in the treatment of thrombotic conditions
|
EP1910361A2
(fr)
*
|
2005-07-28 |
2008-04-16 |
Brystol-Myers Squibb Company |
Tetrahydro-1h-pyrido[4,3,b]indoles substitués en tant qu' agonistes et antagonistes du récepteur de sérotonine
|
EP1757290A1
(fr)
*
|
2005-08-16 |
2007-02-28 |
Zentaris GmbH |
Derivés de triazole comme ligands du recepteur de l'hormone de croissance
|
US7534804B2
(en)
*
|
2005-08-24 |
2009-05-19 |
Bristol-Myers Squibb Company |
Benzoxazole inhibitors of 15-lipoxygenase
|
US7795436B2
(en)
*
|
2005-08-24 |
2010-09-14 |
Bristol-Myers Squibb Company |
Substituted tricyclic heterocycles as serotonin receptor agonists and antagonists
|
WO2007027454A1
(fr)
*
|
2005-08-30 |
2007-03-08 |
Bristol-Myers Squibb Company |
Composes de dihydropyrimidine heterocycliques
|
JP2009506119A
(ja)
|
2005-08-31 |
2009-02-12 |
ユニバーシティ オブ テネシー リサーチ ファウンデーション |
選択的アンドロゲン受容体モジュレーターを用いる腎疾患、熱傷、創傷および脊髄損傷の処置
|
AR056155A1
(es)
*
|
2005-10-26 |
2007-09-19 |
Bristol Myers Squibb Co |
Antagonistas del receptor 1 de la hormona de concentracion de melanina no basica
|
EP1943215A2
(fr)
|
2005-10-31 |
2008-07-16 |
Brystol-Myers Squibb Company |
Inhibiteurs à base d amide et de bêta-amino de pyrrolidinyle de la dipeptidyl peptidase iv et procédés
|
EP1976873A2
(fr)
*
|
2006-01-11 |
2008-10-08 |
Brystol-Myers Squibb Company |
Modulateurs de peptides 1 de type glucagon humain et leur utilisation pour traiter le diabète et des états associés
|
US7553836B2
(en)
*
|
2006-02-06 |
2009-06-30 |
Bristol-Myers Squibb Company |
Melanin concentrating hormone receptor-1 antagonists
|
BRPI0709950A2
(pt)
*
|
2006-04-13 |
2011-08-02 |
Actelion Pharmaceuticals Ltd |
uso de bosentan na preparação de um medicamento para o tratamento de fibrose pulmonar idiopática em estágio precoce e uso de antagonista do receptor endotelin
|
WO2007139589A1
(fr)
*
|
2006-05-26 |
2007-12-06 |
Bristol-Myers Squibb Company |
Modulateurs des récepteurs de glp-1 à libération prolongée
|
US7919598B2
(en)
|
2006-06-28 |
2011-04-05 |
Bristol-Myers Squibb Company |
Crystal structures of SGLT2 inhibitors and processes for preparing same
|
US20080044326A1
(en)
*
|
2006-07-04 |
2008-02-21 |
Esencia Co., Ltd. |
Sterilizer for baby products
|
MX2009000385A
(es)
|
2006-07-12 |
2009-04-06 |
Univ Tennessee Res Foundation |
Acil-anilidas sustituidas y metodos de uso de las mismas.
|
US9730908B2
(en)
|
2006-08-24 |
2017-08-15 |
University Of Tennessee Research Foundation |
SARMs and method of use thereof
|
US7727978B2
(en)
|
2006-08-24 |
2010-06-01 |
Bristol-Myers Squibb Company |
Cyclic 11-beta hydroxysteroid dehydrogenase type I inhibitors
|
US9844528B2
(en)
|
2006-08-24 |
2017-12-19 |
University Of Tennessee Research Foundation |
SARMs and method of use thereof
|
EA016853B1
(ru)
|
2006-08-24 |
2012-08-30 |
Юниверсити Оф Теннесси Рисерч Фаундейшн |
Замещенные ациланилиды и их применение
|
US10010521B2
(en)
|
2006-08-24 |
2018-07-03 |
University Of Tennessee Research Foundation |
SARMs and method of use thereof
|
US7960569B2
(en)
*
|
2006-10-17 |
2011-06-14 |
Bristol-Myers Squibb Company |
Indole antagonists of P2Y1 receptor useful in the treatment of thrombotic conditions
|
US9623021B2
(en)
*
|
2007-01-22 |
2017-04-18 |
Gtx, Inc. |
Nuclear receptor binding agents
|
US9604931B2
(en)
|
2007-01-22 |
2017-03-28 |
Gtx, Inc. |
Nuclear receptor binding agents
|
WO2008091555A2
(fr)
|
2007-01-22 |
2008-07-31 |
Gtx, Inc. |
Agents se liant aux récepteurs nucléaires
|
PE20090185A1
(es)
|
2007-03-22 |
2009-02-28 |
Bristol Myers Squibb Co |
Formulaciones farmaceuticas que contienen un inhibidor sglt2
|
CN101687873A
(zh)
|
2007-04-17 |
2010-03-31 |
百时美施贵宝公司 |
具有稠合杂环的11β-羟基类固醇Ⅰ型脱氢酶抑制剂
|
PE20090696A1
(es)
|
2007-04-20 |
2009-06-20 |
Bristol Myers Squibb Co |
Formas cristalinas de saxagliptina y procesos para preparar las mismas
|
MX2009011089A
(es)
*
|
2007-04-23 |
2009-10-30 |
Sanofi Aventis |
Derivados de quinolina-carboxamida en calidad de antagonistas de p2y12.
|
PE20090222A1
(es)
|
2007-05-04 |
2009-03-27 |
Bristol Myers Squibb Co |
Compuestos [6,6] y [6,7]-biciclicos como agonistas del receptor acoplado a la proteina g gpr119
|
ES2388315T3
(es)
|
2007-05-04 |
2012-10-11 |
Bristol-Myers Squibb Company |
Agonistas [6,5]-bicíclicos de receptores GPR119 acoplados a la proteína G
|
EP2147008A2
(fr)
*
|
2007-05-18 |
2010-01-27 |
Bristol-Myers Squibb Company |
Structures cristallines des inhibiteurs de sglt-2 et procédés pour leur préparation
|
US20090011994A1
(en)
*
|
2007-07-06 |
2009-01-08 |
Bristol-Myers Squibb Company |
Non-basic melanin concentrating hormone receptor-1 antagonists and methods
|
PE20090449A1
(es)
|
2007-07-17 |
2009-04-18 |
Bristol Myers Squibb Co |
Agonistas de receptor acoplado a proteina g gpr119 de piridona
|
JP2010534722A
(ja)
*
|
2007-07-27 |
2010-11-11 |
ブリストル−マイヤーズ スクイブ カンパニー |
新規グルコキナーゼ活性化薬およびその使用方法
|
US7968603B2
(en)
|
2007-09-11 |
2011-06-28 |
University Of Tennessee Research Foundation |
Solid forms of selective androgen receptor modulators
|
EP2238128B1
(fr)
*
|
2007-12-26 |
2012-08-22 |
Sanofi |
Pyrazole-carboxamides hétérocycliques utilisés en tant qu'antagonistes du récepteur p2y12
|
PE20091364A1
(es)
*
|
2008-01-17 |
2009-10-13 |
Novartis Ag |
Proceso para la preparacion de inhibidores de nep
|
EP2103602A1
(fr)
|
2008-03-17 |
2009-09-23 |
AEterna Zentaris GmbH |
Nouveaux dérivés de triazole 1,2,4 et leur processus de fabrication
|
US8148363B2
(en)
|
2008-05-19 |
2012-04-03 |
Schering Corporation |
Heterocyclic compounds as factor IXA inhibitors
|
PE20091928A1
(es)
*
|
2008-05-29 |
2009-12-31 |
Bristol Myers Squibb Co |
Tienopirimidinas hidroxisustituidas como antagonistas de receptor-1 de hormona concentradora de melanina no basicos
|
TW201006821A
(en)
|
2008-07-16 |
2010-02-16 |
Bristol Myers Squibb Co |
Pyridone and pyridazone analogues as GPR119 modulators
|
WO2010111665A1
(fr)
|
2009-03-27 |
2010-09-30 |
Bristol-Myers Squibb Company |
Procédés destinés à prévenir des événements cardiovasculaires indésirables majeurs par des inhibiteurs de la dpp-iv
|
RU2012101214A
(ru)
|
2009-06-16 |
2013-07-27 |
Пфайзер Инк. |
Лекарственные формы апиксабана
|
TWI393716B
(zh)
|
2009-08-04 |
2013-04-21 |
Merck Sharp & Dohme |
作為ixa因子抑制劑之雜環化合物
|
CA2780941C
(fr)
|
2009-11-13 |
2018-06-12 |
Bristol-Myers Squibb Company |
Formulations pour comprimes a liberation immediate
|
HUE040486T2
(hu)
|
2009-11-13 |
2019-03-28 |
Astrazeneca Ab |
Kétrétegû tabletta készítmények
|
EP2498757A1
(fr)
|
2009-11-13 |
2012-09-19 |
Bristol-Myers Squibb Company |
Formulations de metformine a masse reduite
|
TWI562775B
(en)
|
2010-03-02 |
2016-12-21 |
Lexicon Pharmaceuticals Inc |
Methods of using inhibitors of sodium-glucose cotransporters 1 and 2
|
MX2012011460A
(es)
|
2010-04-08 |
2012-11-23 |
Squibb Bristol Myers Co |
Analogos de pirimidinilpiperidiniloxipiridinona como moduladores de gpr119.
|
US8592396B2
(en)
|
2010-04-14 |
2013-11-26 |
Bristol-Myers Squibb Company |
Glucokinase activators and methods of using same
|
MX2012012902A
(es)
|
2010-05-06 |
2012-12-17 |
Bristol Myers Squibb Co |
Analogos heteroarilo biciclicos como moduladores de receptor acoplado a la proteina g gpr119.
|
US8729084B2
(en)
|
2010-05-06 |
2014-05-20 |
Bristol-Myers Squibb Company |
Benzofuranyl analogues as GPR119 modulators
|
KR101476937B1
(ko)
|
2010-08-23 |
2014-12-24 |
노파르티스 아게 |
Nep 억제제의 제조를 위한 중간체의 제조 방법
|
EP2431035A1
(fr)
|
2010-09-16 |
2012-03-21 |
Æterna Zentaris GmbH |
Nouveaux dérivés de triazole avec activité de récepteur améliorée et propriétés de biodisponibilité en tant qu'antagonistes de ghréline de récepteurs de secrétagogue d'hormone de croissance
|
US8993631B2
(en)
|
2010-11-16 |
2015-03-31 |
Novartis Ag |
Method of treating contrast-induced nephropathy
|
ES2581323T3
(es)
|
2010-12-23 |
2016-09-05 |
Purdue Pharma Lp |
Formas de dosificación oral sólida resistentes a alteraciones
|
TWI631963B
(zh)
|
2011-01-05 |
2018-08-11 |
雷西肯製藥股份有限公司 |
包含鈉-葡萄糖共同輸送體1與2之抑制劑的組合物與應用方法
|
CA2853024C
(fr)
|
2011-11-11 |
2017-08-22 |
Pfizer Inc. |
2-thiopyrimidinones
|
CA2869587A1
(fr)
|
2012-04-06 |
2013-10-10 |
Pfizer Inc. |
Inhibiteurs de diacylglycerol acyltransferase 2
|
WO2013173198A1
(fr)
|
2012-05-16 |
2013-11-21 |
Bristol-Myers Squibb Company |
Analogues de pyrimidinylpipéridinyloxypyridone en tant que modulateurs de gpr119
|
SI2858987T1
(en)
|
2012-06-11 |
2018-06-29 |
Bristol-Myers Squibb Company |
PREPARATION OF 5-PHENYL-4- (PYRIDIN-2-ILLETHYLAMINO) -CHUINAZOLIN-2-YL) -PIRIDIN-3-SULPHONAMIDE PHOSPHORAMIDIC ACID
|
US10987334B2
(en)
|
2012-07-13 |
2021-04-27 |
University Of Tennessee Research Foundation |
Method of treating ER mutant expressing breast cancers with selective androgen receptor modulators (SARMs)
|
US10258596B2
(en)
|
2012-07-13 |
2019-04-16 |
Gtx, Inc. |
Method of treating HER2-positive breast cancers with selective androgen receptor modulators (SARMS)
|
US10314807B2
(en)
|
2012-07-13 |
2019-06-11 |
Gtx, Inc. |
Method of treating HER2-positive breast cancers with selective androgen receptor modulators (SARMS)
|
US9622992B2
(en)
|
2012-07-13 |
2017-04-18 |
Gtx, Inc. |
Method of treating androgen receptor (AR)-positive breast cancers with selective androgen receptor modulator (SARMs)
|
US9744149B2
(en)
|
2012-07-13 |
2017-08-29 |
Gtx, Inc. |
Method of treating androgen receptor (AR)-positive breast cancers with selective androgen receptor modulator (SARMs)
|
DK2872482T3
(da)
|
2012-07-13 |
2020-09-21 |
Oncternal Therapeutics Inc |
En fremgangsmåde til behandling af brystkræft med selektiv androgenreceptormodulator (sarm)
|
US9969683B2
(en)
|
2012-07-13 |
2018-05-15 |
Gtx, Inc. |
Method of treating estrogen receptor (ER)-positive breast cancers with selective androgen receptor modulator (SARMS)
|
EP2892897A1
(fr)
|
2012-09-05 |
2015-07-15 |
Bristol-Myers Squibb Company |
Antagonistes du récepteur 1 d'hormone concentrant la mélanine de type pyrrolone ou pyrrolidinone
|
US9586900B2
(en)
|
2012-09-05 |
2017-03-07 |
Bristol-Myers Squibb Company |
Pyrrolone or pyrrolidinone melanin concentrating hormone receptor-1 antagonists
|
TR201815850T4
(tr)
|
2012-11-14 |
2018-11-21 |
Bial Portela & Ca Sa |
Pulmoner arteryel hipertansiyonun ve akciğer hasarının tedavisinde kullanım için 1,3-dihidroimidazol-2-tion türevleri.
|
NZ707859A
(en)
|
2012-11-20 |
2019-03-29 |
Lexicon Pharmaceuticals Inc |
Inhibitors of sodium glucose cotransporter 1
|
US9050345B2
(en)
|
2013-03-11 |
2015-06-09 |
Bristol-Myers Squibb Company |
Pyrrolotriazines as potassium ion channel inhibitors
|
EP2970199A1
(fr)
|
2013-03-11 |
2016-01-20 |
Bristol-Myers Squibb Company |
Isoquinolines servant d'inhibiteurs des canaux ioniques potassiques
|
ES2616025T3
(es)
|
2013-03-11 |
2017-06-09 |
Bristol-Myers Squibb Company |
Pirrolotriazinas como inhibidores de canales de iones potasio
|
CN105008366B
(zh)
|
2013-03-11 |
2017-11-14 |
百时美施贵宝公司 |
作为钾离子通道抑制剂的吡咯并哒嗪类化合物
|
US9242966B2
(en)
|
2013-03-11 |
2016-01-26 |
Bristol-Myers Squibb Company |
Phthalazines as potassium ion channel inhibitors
|
JP6348582B2
(ja)
|
2013-10-09 |
2018-06-27 |
ファイザー・インク |
プロスタグランジンep3受容体の拮抗薬
|
WO2015061272A1
(fr)
|
2013-10-22 |
2015-04-30 |
Bristol-Myers Squibb Company |
Inhibiteurs de triazolopyridine 11-bêta hydroxystéroïde déshydrogénase de type 1 à marquage isotopique
|
EA032356B1
(ru)
|
2014-03-17 |
2019-05-31 |
Пфайзер Инк. |
Ингибиторы диацилглицеринацилтрансферазы 2 для применения в лечении метаболических и связанных с метаболизмом расстройств
|
LT3536685T
(lt)
|
2014-04-04 |
2022-04-25 |
Pfizer Inc. |
Biciklinio sulieto heteroarilo arba arilo junginiai ir jų naudojimas kaip irak4 inhibitorių
|
US9969724B2
(en)
|
2014-04-16 |
2018-05-15 |
Merck Sharp & Dohme Corp. |
Factor IXa inhibitors
|
KR20160147007A
(ko)
|
2014-05-30 |
2016-12-21 |
화이자 인코포레이티드 |
선택적인 안드로겐 수용체 조절제로서의 카보니트릴 유도체
|
EP3237401B1
(fr)
|
2014-12-22 |
2019-03-06 |
Pfizer Inc |
Antagonistes de récepteur ep3 de prostaglandine
|
EP3292109A1
(fr)
|
2015-05-05 |
2018-03-14 |
Pfizer Inc |
2-thiopyrimidinones
|
EP3303303A1
(fr)
|
2015-05-29 |
2018-04-11 |
Pfizer Inc |
Nouveaux composés hétérocycliques utilisés en tant qu'inhibiteurs de l'enzyme vanine-1
|
CN107787322B
(zh)
|
2015-06-17 |
2023-07-07 |
辉瑞大药厂 |
三环化合物以及它们作为磷酸二酯酶抑制剂的用途
|
WO2016203335A1
(fr)
|
2015-06-18 |
2016-12-22 |
Pfizer Inc. |
Nouvelles pyrido [2,3-b] pyrazinones utilisées en tant qu'inhibiteurs de bromodomaines de la famille bet
|
CA2995153A1
(fr)
|
2015-08-13 |
2017-02-16 |
Pfizer Inc. |
Composes aryle ou heteroaryle condenses bicycliques
|
PT3341367T
(pt)
|
2015-08-27 |
2021-04-19 |
Pfizer |
Compostos de arilo ou heteroarilo bicíclicos fusionados como moduladores de irak4
|
WO2017037567A1
(fr)
|
2015-09-03 |
2017-03-09 |
Pfizer Inc. |
Régulateurs de la frataxine
|
SI3397631T1
(sl)
|
2015-12-29 |
2022-01-31 |
Pfizer Inc. |
Substituirani 3-azabiciklo(3.1.0)heksani kot zaviralci ketoheksokinaze
|
AU2017296338A1
(en)
|
2016-07-14 |
2019-01-03 |
Pfizer Inc. |
Novel pyrimidine carboxamides as inhibitors of vanin-1 enzyme
|
JP7072557B2
(ja)
|
2016-07-22 |
2022-05-20 |
ブリストル-マイヤーズ スクイブ カンパニー |
グルコキナーゼ活性化剤およびその使用方法
|
AR109179A1
(es)
|
2016-08-19 |
2018-11-07 |
Pfizer |
Inhibidores de diacilglicerol aciltransferasa 2
|
MA51203A
(fr)
|
2017-11-30 |
2020-10-07 |
Idorsia Pharmaceuticals Ltd |
Combinaison d'un dérivé de 4-pyrimidinesulfamide avec un inhibiteur de sglt-2 pour le traitement de maladies liées à l'endothéline
|
WO2019133445A1
(fr)
|
2017-12-28 |
2019-07-04 |
Inception Ibd, Inc. |
Aminothiazoles utilisés en tant qu'inhibiteurs de vanin-1
|
BR112021000139A2
(pt)
|
2018-07-19 |
2021-04-06 |
Astrazeneca Ab |
Métodos de tratamento da hfpef empregando dapagliflozina e composições compreendendo a mesma
|
US11254660B2
(en)
|
2018-08-31 |
2022-02-22 |
Pfizer Inc. |
Combinations for treatment of NASH/NAFLD and related diseases
|
BR112021004839A2
(pt)
|
2018-09-26 |
2021-06-08 |
Lexicon Pharmaceuticals, Inc. |
formas cristalinas de n-(1-((2-(dimetilamino)etil)amino)-2-metil-1-oxopropan-2-il)-4-(4-(2-metil-5-((2s,3r,4r,5s,6r)-3,4,5-triidróxi-6-(metiltio)tetraidro-2h-piran-2-il)benzil)fenil)butanamida e métodos de sua síntese
|
WO2020102575A1
(fr)
|
2018-11-16 |
2020-05-22 |
Inception Ibd, Inc. |
Aminothiazoles hétérocycliques et leurs utilisations
|
EP3972596A1
(fr)
|
2019-05-20 |
2022-03-30 |
Pfizer Inc. |
Combinaisons comprenant du benzodioxol en tant qu'agonistes de glp-1r destinées à être utilisées dans le traitement de la nash/nafld et de maladies associées
|
TW202115086A
(zh)
|
2019-06-28 |
2021-04-16 |
美商輝瑞大藥廠 |
Bckdk抑制劑
|
US20220363673A1
(en)
|
2019-06-28 |
2022-11-17 |
Pfizer Inc. |
5-(Thiophen-2-YL)-1 H-Tetrazole Derivative as BCKDK Inhibitors Useful for Treating Various Diseases
|
TWI771766B
(zh)
|
2019-10-04 |
2022-07-21 |
美商輝瑞股份有限公司 |
二醯基甘油醯基轉移酶2 抑制劑
|
EP4094759A1
(fr)
|
2019-10-30 |
2022-11-30 |
Perfuse Therapeutics, Inc. |
Traitement de maladies oculaires à l'aide d'antagonistes du récepteur de l'endothéline
|
JP2023512763A
(ja)
*
|
2020-02-06 |
2023-03-29 |
パフューズ セラピューティクス, インコーポレイテッド |
眼疾患の処置のための組成物
|
JP2022058085A
(ja)
|
2020-02-24 |
2022-04-11 |
ファイザー・インク |
ジアシルグリセロールアシルトランスフェラーゼ2阻害剤とアセチル-CoAカルボキシラーゼ阻害剤との組合せ
|
PE20231215A1
(es)
|
2020-06-09 |
2023-08-17 |
Pfizer |
Compuestos espiro como antagonistas del receptor de melanocortina 4 y usos de los mismos
|
US20220023252A1
(en)
|
2020-07-27 |
2022-01-27 |
Astrazeneca Ab |
Methods of treating chronic kidney disease with dapagliflozin
|
KR20240004643A
(ko)
*
|
2021-04-30 |
2024-01-11 |
퍼퓨즈 세라퓨틱스, 인크. |
안구 질환의 치료를 위한 제약 조성물 및 유리체내 약물 전달 시스템
|
JPWO2022270487A1
(fr)
|
2021-06-22 |
2022-12-29 |
|
|
WO2023275715A1
(fr)
|
2021-06-30 |
2023-01-05 |
Pfizer Inc. |
Métabolites de modulateurs sélectifs du récepteur des androgènes
|
WO2023026180A1
(fr)
|
2021-08-26 |
2023-03-02 |
Pfizer Inc. |
Forme amorphe de (s)-2-(5-((3-éthoxypyridin-2-yl)oxy)pyridin-3-yl)-n-(tétrahydrofuran-3-yl)pyrimidine-5-carboxamide
|
TW202337429A
(zh)
|
2021-12-01 |
2023-10-01 |
美商輝瑞股份有限公司 |
支鏈酮酸脫氫酶激酶(bckdk)抑制劑及/或降解劑
|
WO2023105387A1
(fr)
|
2021-12-06 |
2023-06-15 |
Pfizer Inc. |
Antagonistes du récepteur 4 de la mélanocortine et leurs utilisations
|
WO2023144722A1
(fr)
|
2022-01-26 |
2023-08-03 |
Astrazeneca Ab |
Dapagliflozine destinée à être utilisée dans le traitement du prédiabète ou pour réduire le risque de développer un diabète de type 2
|
WO2023169456A1
(fr)
|
2022-03-09 |
2023-09-14 |
Gasherbrum Bio , Inc. |
Agonistes hétérocycliques de glp-1
|
WO2023198140A1
(fr)
|
2022-04-14 |
2023-10-19 |
Gasherbrum Bio, Inc. |
Agonistes hétérocycliques de glp-1
|
WO2024075051A1
(fr)
|
2022-10-07 |
2024-04-11 |
Pfizer Inc. |
Inhibiteurs et/ou agents de dégradation de hsd17b13
|
WO2024084360A1
(fr)
|
2022-10-18 |
2024-04-25 |
Pfizer Inc. |
Modificateurs de la proteine 3 contenant le domaine phospholipase de type patatine (pnpla3)
|
WO2024084390A1
(fr)
|
2022-10-18 |
2024-04-25 |
Pfizer Inc. |
Composés pour l'activation de l'ampk
|